Building Diagnostics Without Building Hardware: Checktor’s Strategic Play
In this episode of Diagnosing Dx, I’m joined by Jake Lesinski, Co-founder and CEO of Checktor Biosciences, an ETH Zurich spin-out building a CRISPR-based chemistry platform designed to upgrade existing diagnostic systems rather than replace them.
We explore why speed, decentralisation, and practical integration, not hype, will define the next wave of molecular diagnostics. Jake shares how Checktor is approaching CRISPR from a clinical and commercial perspective, why matching PCR-level performance matters, and how distribution strategy can make or break even the strongest science.
This…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.